Detalles de la búsqueda
1.
The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo.
Anticancer Drugs
; 34(4): 532-543, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36729959
2.
Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models.
Anticancer Drugs
; 34(9): 1035-1045, 2023 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36729099
3.
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.
Br J Cancer
; 123(9): 1360-1369, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32741975
4.
ERBB receptors and cancer: the complexity of targeted inhibitors.
Nat Rev Cancer
; 5(5): 341-54, 2005 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-15864276
5.
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Breast Cancer Res
; 14(5): R132, 2012 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-23075476
6.
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
Neuro Oncol
; 24(3): 384-395, 2022 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34232318
7.
Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
Anticancer Drugs
; 22(1): 58-78, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20890178
8.
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.
Nat Med
; 10(6): 594-601, 2004 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15156201
9.
Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.
Proc Natl Acad Sci U S A
; 105(36): 13544-9, 2008 Sep 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-18768809
10.
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
JCI Insight
; 6(18)2021 09 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34403371
11.
AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.
Clin Cancer Res
; 15(4): 1277-87, 2009 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19228731
12.
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Clin Cancer Res
; 15(5): 1612-22, 2009 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19223496
13.
Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
Mol Cancer Ther
; 8(4): 742-53, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19372546
14.
EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis.
Oncotarget
; 11(8): 759-774, 2020 Feb 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-32165998
15.
PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel.
Clin Cancer Res
; 14(12): 3993-4001, 2008 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18559622
16.
The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
Cancer Res
; 67(14): 6956-64, 2007 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17638907
17.
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.
Mol Cancer Ther
; 7(5): 1237-45, 2008 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-18483311
18.
Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.
Cell Rep
; 25(11): 3047-3058.e4, 2018 12 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30540938
19.
The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.
Radiother Oncol
; 124(3): 433-438, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28797699
20.
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Semin Oncol
; 33(2 Suppl 7): S18-25, 2006 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-16730273